| Pair Name | Ginsenoside Rh2, Gemcitabine | ||
| Phytochemical Name | Ginsenoside Rh2 (PubChem CID: 119307 ) | ||
| Anticancer drug Name | Gemcitabine (PubChem CID: 60750 ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Pair Name | Ginsenoside Rh2, Gemcitabine | |||
| Disease Info | [ICD-11: 2C10] | Pancreatic cancer | Investigative | |
| Biological Phenomena | Induction-->Immunomodulatory | |||
| Gene Regulation | Up-regulation | Expression | BAX | hsa581 |
| Up-regulation | Expression | BCL10 | hsa8915 | |
| Down-regulation | Expression | BCL2 | hsa596 | |
| Up-regulation | Expression | CARD9 | hsa64170 | |
| Up-regulation | Cleavage | CASP3 | hsa836 | |
| Up-regulation | Expression | MALT1 | hsa10892 | |
| Up-regulation | Expression | NFKB1 | hsa4790 | |
| In Vitro Model | Panc02 | Mouse pancreatic ductal adenocarcinoma | Mus musculus (Mouse) | CVCL_D627 |
| PANC-1 | Pancreatic ductal adenocarcinoma | Homo sapiens (Human) | CVCL_0480 | |
| In Vivo Model | Orthotopic mouse model: Panc02 cells engineered to stably express firefly luciferase (1×10⁶) were mixed in an equal volume of Matrigel and were injected into the tail of pancreas of each mouse. | |||
| Result | Rh2 activation of DCs may remodel the cold TIME and optimize GEM chemotherapy for future therapeutic use. | |||
| No. | Title | Href |
|---|---|---|
| 1 | The combination of gemcitabine and ginsenoside Rh2 enhances the immune function of dendritic cells against pancreatic cancer via the CARD9-BCL10-MALT1 / NF-κB pathway. Clin Immunol. 2023 Mar;248:109217. doi: 10.1016/j.clim.2022.109217. | Click |
